

ASSIGNMENT

For good and valuable consideration, the sufficiency and receipt of which is hereby acknowledged, the person(s) named below (referred to as "INVENTOR" whether singular or plural) has sold, assigned, and transferred and does hereby sell, assign, and transfer to VOYAGER THERAPEUTICS, INC., having a place of business at 75 Sidney Street, Cambridge, Massachusetts 02139 ("ASSIGNEE"), for itself and its successors, transferees, and assigns (herein "ASSIGNEE") the following:

1. The entire worldwide right, title, and interest in all inventions and improvements ("SUBJECT MATTER") that are disclosed in the following provisional application filed under 35 U.S.C. § 111(b), non-provisional application filed under 35 U.S.C. § 111(a), international application filed according to the Patent Cooperation Treaty (PCT), or U.S. national phase application filed under 35 U.S.C. § 371 ("APPLICATION"):

- Application No. PCT/US2018/037437, entitled "AADC POLYNUCLEOTIDES FOR THE TREATMENT OF PARKINSON'S DISEASE", filed on June 14, 2018 which claims priority to U.S. Application No. 62/520,084 filed June 15, 2017 entitled "AADC POLYNUCLEOTIDES FOR THE TREATMENT OF PARKINSON'S DISEASE" and U.S. Application No. 62/554,155 filed September 5, 2017 entitled "AADC POLYNUCLEOTIDES FOR THE TREATMENT OF PARKINSON'S DISEASE".

2. The entire worldwide right, title, and interest in and to:
(a) the APPLICATION; (b) all applications claiming priority from the APPLICATION; (c) all provisional, utility, divisional, continuation, substitute, renewal, reissue, and other applications related thereto which have been or may be filed in the United States or elsewhere in the world; (d) all patents (including reissues and re-examinations) which may be granted on the applications set forth in (a), (b), and (c) above; and (e) all right of priority in the APPLICATION and in any underlying provisional or foreign application, together with all rights to sue for and recover damages for past acts of infringement, whether based on any patents listed herein, patents issuing from applications listed herein or provisional rights from any patent application listed herein.

INVENTOR agrees that ASSIGNEE may apply for and receive patents for SUBJECT MATTER in ASSIGNEE's own name.

INVENTOR agrees to do the following, when requested, and without further consideration, in order to carry out the intent of this Assignment: (1) execute all oaths, assignments, powers of attorney, applications, and other papers necessary or desirable to fully secure to ASSIGNEE the rights, titles and interests herein conveyed; (2) communicate to ASSIGNEE all known facts relating to the SUBJECT MATTER; and (3) generally do all lawful acts that ASSIGNEE shall consider desirable for securing, maintaining, and enforcing worldwide patent protection relating to the SUBJECT MATTER and for vesting in ASSIGNEE the rights, titles, and interests herein conveyed. INVENTOR further agrees to provide any successor,

Title: AADC POLYNUCLEOTIDES FOR THE TREATMENT OF PARKINSON'S DISEASE

Filed: June 14, 2018

Application No: PCT/US2018/037437


assign, or legal representative of ASSIGNEE with the benefits and assistance provided to ASSIGNEE hereunder.

INVENTOR represents that INVENTOR has the rights, titles, and interests to convey as set forth herein, and covenants with ASSIGNEE that the INVENTOR has not made and will not hereafter make any assignment, grant, mortgage, license, or other agreement affecting the rights, titles, and interests herein conveyed.

INVENTOR grants the attorney of record the power to insert on this Assignment any further identification that may be necessary or desirable to comply with the rules of the United States Patent and Trademark Office for recordation of this document.


INVENTOR acknowledges the duty to disclose information which is material to patentability as defined in 37 CFR 1.56, including for continuation-in-part applications, material information which became available between the filing date of the prior application and the national or PCT international filing date of the continuation-in-part application.

This Assignment may be executed in one or more counterparts, each of which shall be deemed an original and all of which may be taken together as one and the same Assignment.

Date Sep. 9th 2018 Signature 
Name Maria Scheel

Date July 17 2018 Signature 
Name Bernard Ravina

The undersigned acknowledges and accepts this assignment on behalf of VOYAGER THERAPEUTICS, INC.

Date 12 Sep 2018 Signature 
Dinah Wen-Yee Sah, Authorized Representative of
VOYAGER THERAPEUTICS, INC.